A three-year experience of the Referral Center for Surgical Treatment of Gastroesophageal Reflux Disease.

AIM: Gastro-esophageal reflux disease (GERD) rapresents the fastest growing disease affecting the alimentary and breathing apparatus. Incidence of esophageal adenocarcinoma with Barrett Esophagus (BE) imposes a decision about therapy management. METHODS: Between January 2006 to December 2009, 3 653 patients were subjected to our observation; 2 095 patients underwent endoscopy (57.4%), of these 598 underwent twenty-four hours pH-Metry (16.3%); 1 558 patients (42.6%) had clinical consult. RESULTS: A total of 1 255/2 095 referred typical symptoms (60%), 644 patients typical and atypical symptoms (30.7%), 96 patients atypical symptoms (4.6%); 4.7% had dysfagia and cramps; 1 897 patients (90.5%) had Los Angeles A esophagitis, 62 Los Angeles B (2.96%), 6 had Shatzki Ring (0.3%). NERD in 26 patients (1.24%); 3.4% had Hp Gastritis; 33 had BE (1.6%), 10 intestinalized type (30.3%), 23 gatric type (69.7%). Eighty-five/2 095 patients (4%, 36 M and 49 F, m.a. 42.5 years, range 20-72) underwent laparoscopic Nissen-Rossetti Fundoplication (4%), 69 with preoperative typical symptoms (81%), 11 typical and atypical symptoms (13%), 5 atypical symptoms (6%). Twenty-three had BE (27%, 9 intestinal metaplasia, 3 Long and 6 Short Barrett, 14 Gastric metaplasia); 61 with Los Angeles A esophagitis (98.3%), 1 with Shatzki Ring (1.7%). PH-Metries were positive. CONCLUSION: GERD requires specialistic and qualified centers.

Total fundoplication without division of the short gastric vessels: functional evaluation at one year and review of literature.

AIM: Gastro-esophageal reflux disease (GERD) has emerged as one of the most common diseases in modern civilization. We investigated functional evaluation after total fundoplication without division of short gastric vessels and review of literature. METHODS: From January 2007 to June 2008 43 patients with chronic gastroesophageal reflux underwent laparoscopic Nissen-Rossetti fundoplication, 7 were lost during the follow-up. Patients underwent endoscopy, 24 hours pH-Metry, preoperatively, 6 months and 12 months after surgery. Articles were sourced from PubMed and Medline, using the MeSH terms "gastroesophageal reflux disease" and "laparoscopic surgery" and "fundoplication technique". Selection of articles were based on peer review, journal, relevance and English language. RESULTS: Endoscopic findings revealed complete healing of esophagitis in all patients. Barrett esophagus was still present. Six patients reported persistence of symptoms but postoperative pH-metry and endoscopy showed the absence of reflux; two patients (5.5%) were still on PPI therapy at 12 months. Seven patients (19.4%) reported dysphagia for solid for at least three months. Re-admission for dysphagia was required for two (5.5%) and one patient underwent to endoscopic dilatation. At six and 12 months no dysphagia was reported. During the follow-up no gas-bloat syndrome was referred. The Johnsson and DeMeester's score reduction from six months to 12 months was statistically significant. Randomized and non-randomized studies seem to point out in a precise way that a division of short gastric vessels is unnecessary to perform a "short and floppy" placation. CONCLUSION: Nissen-Rossetti fundoplication is safe and effective for treatment of GERD, with minimal post-operative side effects.

Barrett's esophagus after laparoscopic Nissen-Rossetti fundoplication: functional evaluation.

AIM: The aim of this study was to demonstrate the efficacy of laparoscopic antireflux surgery in controlling Barrett's esophagus progression, through functional study. METHODS: Between January 2008 and December 2009, 21 patients with a preoperative diagnosis of Barrett's esophagus underwent Nissen-Rossetti fundoplication. RESULTS: All patients underwent preoperatively a 24-hour pH-metry (100%). Twenty patients (95.2%) had postoperative pH monitoring at six months, 16 patients at 12 months (76.2%), eight at 24 months (57.14%). Median De Meester and Johnson score was preoperatively 18.55 (range 8.6-179.7), at six months 7.65 (range 6.4-13), at 12 months 7.5 (range 6.4-14.2), at 24 months 11.95 (range 6.4-20.6). CLE was still present in 18 patients (18/21, 85.7%), but no patient developed dysplasia or esophageal adenocarcinoma. Two patients with gastric- and one patient with intestinal metaplasia showed complete regression at 12 and 24 months after fundoplication (3/21, 14.3%). Symptom control alone does not manage acid reflux in patients with Barrett's esophagus after surgery, and postoperative 24-hour pH-metry confirms acid reflux abolition. A persistent reflux is more likely to develop cancer than in monitored patients. CONCLUSION: Only the presence of intact and effective anti-reflux wrap guarantees protection of the esophagus against CLE progression or its regression. Functional study after surgery identifies patients with Barrett's progression risk.